SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jagsonpal Pharmaceuticals informs about press release

16 Aug 2021 Evaluate

In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, Jagsonpal Pharmaceuticals has informed that it enclosed a copy of the Press Release on the Unaudited Financial results of the Company for the quarter ended 30th June, 2021.

The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharma Share Price

210.75 3.95 (1.91%)
06-May-2026 11:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.00
Dr. Reddys Lab 1298.75
Cipla 1356.55
Zydus Lifesciences 935.10
Lupin 2421.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×